Biotinylated Human Siglec-7 / CD328 Protein, His,Avitag? (MALS & SPR verified)
分子別名（Synonym）
CDw328,D-siglec,A79 membrane protein,p75,Adhesion inhibitory receptor molecule 1, AIRM-1
表達區(qū)間及表達系統(tǒng)（Source）
Biotinylated Human Siglec-7, His,Avitag (SG7-H82E7) is expressed from human 293 cells (HEK293). It contains AA Gln 19 - Leu 353 (Accession # Q9Y286-1).
Predicted N-terminus: Gln 19
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 40.5 kDa. The protein migrates as 55-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
標記（Biotinylation）
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標記度（Biotin:Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in 25 mM MES, 150 mM NaCl, pH5.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
Siglec-7是人類CD33相關(guān)Siglec受體的成員。Siglec-7的細胞外區(qū)域以一個可以結(jié)合唾液酸的N端V集Ig結(jié)構(gòu)域和兩個C2集Ig結(jié)構(gòu)區(qū)為特征。Siglec-7的細胞質(zhì)尾部有一個免疫受體酪氨酸基抑制基序（ITIM）和一個ITIM樣基序。Siglec-7被認為是一種具有抑制潛力的唾液酸依賴性免疫受體，主要在人NK細胞、單核細胞和一小部分CD8+T細胞上表達。
關(guān)鍵字： Siglec-7;Siglec-7蛋白;Siglec-7重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。